These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

352 related articles for article (PubMed ID: 31866327)

  • 1. Adverse events in adults with latent tuberculosis infection receiving daily rifampicin or isoniazid: post-hoc safety analysis of two randomised controlled trials.
    Campbell JR; Trajman A; Cook VJ; Johnston JC; Adjobimey M; Ruslami R; Eisenbeis L; Fregonese F; Valiquette C; Benedetti A; Menzies D
    Lancet Infect Dis; 2020 Mar; 20(3):318-329. PubMed ID: 31866327
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Rifamycins (rifampicin, rifabutin and rifapentine) compared to isoniazid for preventing tuberculosis in HIV-negative people at risk of active TB.
    Sharma SK; Sharma A; Kadhiravan T; Tharyan P
    Cochrane Database Syst Rev; 2013 Jul; 2013(7):CD007545. PubMed ID: 23828580
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Health System Costs of Treating Latent Tuberculosis Infection With Four Months of Rifampin Versus Nine Months of Isoniazid in Different Settings.
    Bastos ML; Campbell JR; Oxlade O; Adjobimey M; Trajman A; Ruslami R; Kim HJ; Baah JO; Toelle BG; Long R; Hoeppner V; Elwood K; Al-Jahdali H; Apriani L; Benedetti A; Schwartzman K; Menzies D
    Ann Intern Med; 2020 Aug; 173(3):169-178. PubMed ID: 32539440
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Adverse events with 4 months of rifampin therapy or 9 months of isoniazid therapy for latent tuberculosis infection: a randomized trial.
    Menzies D; Long R; Trajman A; Dion MJ; Yang J; Al Jahdali H; Memish Z; Khan K; Gardam M; Hoeppner V; Benedetti A; Schwartzman K
    Ann Intern Med; 2008 Nov; 149(10):689-97. PubMed ID: 19017587
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An open label, randomised controlled trial of rifapentine versus rifampicin based short course regimens for the treatment of latent tuberculosis in England: the HALT LTBI pilot study.
    Surey J; Stagg HR; Yates TA; Lipman M; White PJ; Charlett A; Muñoz L; Gosce L; Rangaka MX; Francis M; Hack V; Kunst H; Abubakar I
    BMC Infect Dis; 2021 Jan; 21(1):90. PubMed ID: 33478428
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety and Side Effects of Rifampin versus Isoniazid in Children.
    Diallo T; Adjobimey M; Ruslami R; Trajman A; Sow O; Obeng Baah J; Marks GB; Long R; Elwood K; Zielinski D; Gninafon M; Wulandari DA; Apriani L; Valiquette C; Fregonese F; Hornby K; Li PZ; Hill PC; Schwartzman K; Benedetti A; Menzies D
    N Engl J Med; 2018 Aug; 379(5):454-463. PubMed ID: 30067928
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Flu-like and Other Systemic Drug Reactions Among Persons Receiving Weekly Rifapentine Plus Isoniazid or Daily Isoniazid for Treatment of Latent Tuberculosis Infection in the PREVENT Tuberculosis Study.
    Sterling TR; Moro RN; Borisov AS; Phillips E; Shepherd G; Adkinson NF; Weis S; Ho C; Villarino ME;
    Clin Infect Dis; 2015 Aug; 61(4):527-35. PubMed ID: 25904367
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rifamycins (rifampicin, rifabutin and rifapentine) compared to isoniazid for preventing tuberculosis in HIV-negative people at risk of active TB.
    Sharma SK; Sharma A; Kadhiravan T; Tharyan P
    Evid Based Child Health; 2014 Mar; 9(1):169-294. PubMed ID: 25404581
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Four Months of Rifampin or Nine Months of Isoniazid for Latent Tuberculosis in Adults.
    Menzies D; Adjobimey M; Ruslami R; Trajman A; Sow O; Kim H; Obeng Baah J; Marks GB; Long R; Hoeppner V; Elwood K; Al-Jahdali H; Gninafon M; Apriani L; Koesoemadinata RC; Kritski A; Rolla V; Bah B; Camara A; Boakye I; Cook VJ; Goldberg H; Valiquette C; Hornby K; Dion MJ; Li PZ; Hill PC; Schwartzman K; Benedetti A
    N Engl J Med; 2018 Aug; 379(5):440-453. PubMed ID: 30067931
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment for preventing tuberculosis in children and adolescents: a randomized clinical trial of a 3-month, 12-dose regimen of a combination of rifapentine and isoniazid.
    Villarino ME; Scott NA; Weis SE; Weiner M; Conde MB; Jones B; Nachman S; Oliveira R; Moro RN; Shang N; Goldberg SV; Sterling TR; ;
    JAMA Pediatr; 2015 Mar; 169(3):247-55. PubMed ID: 25580725
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Factors associated with treatment adherence in a randomised trial of latent tuberculosis infection treatment.
    Trajman A; Long R; Zylberberg D; Dion MJ; Al-Otaibi B; Menzies D
    Int J Tuberc Lung Dis; 2010 May; 14(5):551-9. PubMed ID: 20392347
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Latent tuberculosis infection treatment for prison inmates: a randomised controlled trial.
    Chan PC; Yang CH; Chang LY; Wang KF; Lu BY; Lu CY; Shao PL; Hsueh PR; Fang CT; Huang LM
    Int J Tuberc Lung Dis; 2012 May; 16(5):633-8. PubMed ID: 22410137
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Rifampin and pyrazinamide vs isoniazid for prevention of tuberculosis in HIV-infected persons: an international randomized trial. Terry Beirn Community Programs for Clinical Research on AIDS, the Adult AIDS Clinical Trials Group, the Pan American Health Organization, and the Centers for Disease Control and Prevention Study Group.
    Gordin F; Chaisson RE; Matts JP; Miller C; de Lourdes Garcia M; Hafner R; Valdespino JL; Coberly J; Schechter M; Klukowicz AJ; Barry MA; O'Brien RJ
    JAMA; 2000 Mar; 283(11):1445-50. PubMed ID: 10732934
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment of Latent Tuberculosis Infection: An Updated Network Meta-analysis.
    Zenner D; Beer N; Harris RJ; Lipman MC; Stagg HR; van der Werf MJ
    Ann Intern Med; 2017 Aug; 167(4):248-255. PubMed ID: 28761946
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Self-administered Versus Directly Observed Once-Weekly Isoniazid and Rifapentine Treatment of Latent Tuberculosis Infection: A Randomized Trial.
    Belknap R; Holland D; Feng PJ; Millet JP; Caylà JA; Martinson NA; Wright A; Chen MP; Moro RN; Scott NA; Arevalo B; Miró JM; Villarino ME; Weiner M; Borisov AS;
    Ann Intern Med; 2017 Nov; 167(10):689-697. PubMed ID: 29114781
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of 3 Months of Once-Weekly Rifapentine and Isoniazid for Latent Tuberculosis Infection.
    Walker RE; Bass S; Srinivas P; Miranda C; Johnson L; Pallotta AM
    Ann Pharmacother; 2020 May; 54(5):457-463. PubMed ID: 31729245
    [No Abstract]   [Full Text] [Related]  

  • 17. Treatment of latent tuberculosis infection: An update.
    Lobue P; Menzies D
    Respirology; 2010 May; 15(4):603-22. PubMed ID: 20409026
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Three months of rifapentine and isoniazid for latent tuberculosis infection in hemodialysis patients: High rates of adverse events.
    Lin SY; Chiu YW; Lu PL; Hwang SJ; Chen TC; Hsieh MH; Chen YH
    J Microbiol Immunol Infect; 2019 Feb; 52(1):158-162. PubMed ID: 29907535
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rifampicin plus pyrazinamide versus isoniazid for treating latent tuberculosis infection: a meta-analysis.
    Gao XF; Wang L; Liu GJ; Wen J; Sun X; Xie Y; Li YP
    Int J Tuberc Lung Dis; 2006 Oct; 10(10):1080-90. PubMed ID: 17044199
    [TBL] [Abstract][Full Text] [Related]  

  • 20. High-dose, short-duration versus standard rifampicin for tuberculosis preventive treatment: a partially blinded, three-arm, non-inferiority, randomised, controlled trial.
    Ruslami R; Fregonese F; Apriani L; Barss L; Bedingfield N; Chiang V; Cook VJ; Fisher D; Flores E; Fox GJ; Johnston J; Lim RK; Long R; Paulsen C; Nguyen TA; Nhung NV; Gibson D; Valiquette C; Benedetti A; Menzies D
    Lancet Respir Med; 2024 Jun; 12(6):433-443. PubMed ID: 38552659
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.